144060-53-7 | 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$8.00	$5.00
100mg	98%	in stock	$10.00	$7.00
1g	98%	in stock	$13.00	$9.00
5g	98%	in stock	$25.00	$17.00
25g	98%	in stock	$82.00	$57.00
100g	98%	in stock	$263.00	$184.00
500g	98%	in stock	$758.00	$531.00

Description

• Catalog Number: AB49806
• Chemical Name: 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
• CAS Number: 144060-53-7
• Molecular Formula: C16H16N2O3S
• Molecular Weight: 316.3748
• MDL Number: MFCD00871598
• SMILES: N#Cc1cc(ccc1OCC(C)C)c1nc(c(s1)C(=O)O)C
• NSC Number: 758874

Computed Properties

• Complexity: 448
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 3.9

Literature

• Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells.

  Journal of applied toxicology : JAT 20160901

• Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation.

  Experimental cell research 20160315

• Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats.

  Chemico-biological interactions 20150725

• Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.

  Seminars in arthritis and rheumatism 20130601

• Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in dog plasma and its application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20130201

• Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.

  Anti-inflammatory & anti-allergy agents in medicinal chemistry 20130101

• Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.

  Bioorganic & medicinal chemistry letters 20121215

• The rheumatology of gout.

  Advances in chronic kidney disease 20121101

• Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.

  Biochemical and biophysical research communications 20121019

• Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.

  Seminars in arthritis and rheumatism 20121001

• Pharmacokinetics of febuxostat in healthy Chinese volunteers.

  Arzneimittel-Forschung 20121001

• The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

  British journal of clinical pharmacology 20120801

• Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.

  Evidence-based medicine 20120801

• Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.

  Clinical and experimental nephrology 20120801

• [Gout and other crystal-induced arthritides].

  Deutsche medizinische Wochenschrift (1946) 20120801

• Casebook consults: improving outcomes in gout (multimedia activity).

  The American journal of medicine 20120801

• Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.

  American heart journal 20120701

• Pegloticase for treating refractory chronic gout.

  Drugs of today (Barcelona, Spain : 1998) 20120701

• Recent advances in management of gout.

  QJM : monthly journal of the Association of Physicians 20120501

• Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.

  Bioorganic & medicinal chemistry 20120501

• The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.

  International journal of clinical pharmacology and therapeutics 20120501

• [Gout: an overview of available urate lowering therapies].

  Annales pharmaceutiques francaises 20120501

• Gout and organ transplantation.

  Current rheumatology reports 20120401

• [Medication of the month. Febuxostat (Adenuric)].

  Revue medicale de Liege 20120401

• Hyperuricemia, gout and the kidney.

  Current opinion in rheumatology 20120301

• Febuxostat hypersensitivity.

  The Journal of rheumatology 20120301

• [Pharmacological sheet. Febuxostat, oral (Adenuric)].

  Journal de pharmacie de Belgique 20120301

• Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.

  Arthritis care & research 20120201

• Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.

  The Medical journal of Malaysia 20120201

• Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.

  Rheumatology international 20120101

• An update on the pathology and clinical management of gouty arthritis.

  Clinical rheumatology 20120101

• Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial.

  BMC medicine 20120101

• African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

  BMC musculoskeletal disorders 20120101

• Gout and the risk for incident heart failure and systolic dysfunction.

  BMJ open 20120101

• The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

  BMC geriatrics 20120101

• Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics.

  Scientific reports 20120101

• Redox proteomics identification of oxidatively modified myocardial proteins in human heart failure: implications for protein function.

  PloS one 20120101

• Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique.

  Journal of pharmaceutical and biomedical analysis 20111205

• [Treatment of gout].

  La Revue de medecine interne 20111201

• Comorbidities in gouty arthritis.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20111201

• [Hyperuricemia, gout, pseudogout and concomitant diseases].

  Deutsche medizinische Wochenschrift (1946) 20111201

• Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.

  Nucleosides, nucleotides & nucleic acids 20111201

• 2011 Recommendations for the diagnosis and management of gout and hyperuricemia.

  Postgraduate medicine 20111101

• 2011 recommendations for the diagnosis and management of gout and hyperuricemia.

  The Physician and sportsmedicine 20111101

• Management of gout in the older adult.

  The American journal of geriatric pharmacotherapy 20111001

• Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20111001

• Efficacy and safety of febuxostat in patients with hyperuricemia and gout.

  Therapeutic advances in musculoskeletal disease 20111001

• [New therapeutic options for gout].

  Presse medicale (Paris, France : 1983) 20110901

• Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.

  The Journal of rheumatology 20110901

• Nickel-catalyzed C-H arylation of azoles with haloarenes: scope, mechanism, and applications to the synthesis of bioactive molecules.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20110829

• Gout and transplantation: new treatment option-same old drug interaction.

  Transplantation 20110815

• Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstates.

  Journal of cardiovascular translational research 20110801

• Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.

  Clinical journal of the American Society of Nephrology : CJASN 20110801

• The challenges of gout management in the elderly.

  Drugs & aging 20110801

• [Gout - regardless of therapeutic options a 'forgotten' disease].

  Deutsche medizinische Wochenschrift (1946) 20110801

• Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.

  Annals of the rheumatic diseases 20110701

• Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.

  Free radical biology & medicine 20110701

• Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.

  The Journal of rheumatology 20110701

• [Febuxostat].

  Deutsche medizinische Wochenschrift (1946) 20110601

• Febuxostat efficacy in allopurinol-resistant tophaceous gout.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601

• Managing your patient with gout: a review of treatment options.

  Postgraduate medicine 20110501

• Febuxostat methanol solvate.

  Acta crystallographica. Section E, Structure reports online 20110501

• Developing potent human uric acid transporter 1 (hURAT1) inhibitors.

  Journal of medicinal chemistry 20110428

• Febuxostat for treatment of chronic gout.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110301

• Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.

  Journal of clinical pharmacology 20110201

• Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.

  PharmacoEconomics 20110201

• Gout therapeutics: new drugs for an old disease.

  Lancet (London, England) 20110108

• Renal function in gout: long-term treatment effects of febuxostat.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110101

• Treatment of gout.

  Internal medicine journal 20110101

• A case series of allopurinol-induced toxic epidermal necrolysis.

  Indian journal of dermatology 20110101

• Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma.

  Case reports in medicine 20110101

• Renal co-morbidity in patients with rheumatic diseases.

  Arthritis research & therapy 20110101

• The Relation between Fructose-Induced Metabolic Syndrome and Altered Renal Haemodynamic and Excretory Function in the Rat.

  International journal of nephrology 20110101

• Multiarticular chronic tophaceous gout with severe and multiple ulcerations: a case report.

  Journal of medical case reports 20110101

• Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.

  PloS one 20110101

• The role of the NLRP3 inflammasome in gout.

  Journal of inflammation research 20110101

• Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus.

  PloS one 20110101

• Calciphylaxis presenting in early chronic kidney disease with mixed hyperparathyroidism.

  International journal of nephrology and renovascular disease 20110101

• Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.

  Journal of blood medicine 20110101

• [Current management of gout].

  Acta medica portuguesa 20110101

• Febuxostat: a novel agent for management of hyperuricemia in gout.

  Indian journal of pharmaceutical sciences 20110101

• Crystal arthropathies: recognizing and treating 'the gouch'.

  Primary care 20101201

• Managing gout: how is it different in patients with chronic kidney disease?

  Cleveland Clinic journal of medicine 20101201

• Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

  Clinical therapeutics 20101201

• [Therapy of acute gout attack. It need not always be NSAID].

  MMW Fortschritte der Medizin 20101125

• The current state of care in gout: Addressing the need for better understanding of an ancient disease.

  Journal of the American Academy of Nurse Practitioners 20101101

• Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure?

  Chinese medical journal 20100901

• International position paper on febuxostat.

  Clinical rheumatology 20100801

• Managing gout in the primary care setting: what you and your patients need to know.

  The American journal of medicine 20100801

• Febuxostat for gout.

  Drug and therapeutics bulletin 20100701

• Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.

  British journal of clinical pharmacology 20100701

• Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors.

  European journal of medicinal chemistry 20100601

• High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.

  Diabetes care 20100601

• Urate-lowering therapy for gout: focus on febuxostat.

  Pharmacotherapy 20100601

• Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction.

  Nucleosides, nucleotides & nucleic acids 20100601

• New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.

  Current rheumatology reports 20100401

• Progress in the pharmacotherapy of gout.

  Current opinion in rheumatology 20100301

• Febuxostat provides new gout treatment option.

  The Nurse practitioner 20100301

• Update on gout and hyperuricemia.

  International journal of clinical practice 20100201

• New Drugs2010, PART 1.

  Nursing 20100201

• Update on gout: new therapeutic strategies and options.

  Nature reviews. Rheumatology 20100101

• Management of hyperuricemia in gout: focus on febuxostat.

  Clinical interventions in aging 20100101

• The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

  Arthritis research & therapy 20100101

• [The clinical picture of gout is changing].

  Duodecim; laaketieteellinen aikakauskirja 20100101

• Advances in gout: some answers, more questions.

  Arthritis research & therapy 20100101

• New advances in the treatment of gout: review of pegloticase.

  Therapeutics and clinical risk management 20100101

• [Gout and comorbidities associated with hyperuricemia].

  Annales Academiae Medicae Stetinensis 20100101

• Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.

  International journal of nephrology and renovascular disease 20100101

• New and improved strategies for the treatment of gout.

  International journal of nephrology and renovascular disease 20100101

• [Crystal-induced activation of the inflammasome: gout and pseudogout].

  Zeitschrift fur Rheumatologie 20091101

• Approach to the treatment of hyperuricemia.

  Medicine and health, Rhode Island 20091101

• Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

  Clinical therapeutics 20091101

• 2-[3-Cyano-4-(2-methyl-prop-oxy)phen-yl]-4-methyl-thia-zole-5-carboxylic acid pyridine solvate.

  Acta crystallographica. Section E, Structure reports online 20091101

• Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.

  Health technology assessment (Winchester, England) 20091001

• Gout Study Group: update on hyperuricemia and gout.

  Joint, bone, spine : revue du rhumatisme 20090701

• Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

  The Journal of rheumatology 20090601

• Gout--what are the treatment options?

  Expert opinion on pharmacotherapy 20090601

• Febuxostat (Uloric) for chronic treatment of gout.

  The Medical letter on drugs and therapeutics 20090518

• Febuxostat: a new treatment for hyperuricaemia in gout.

  Rheumatology (Oxford, England) 20090501

• Nickel-catalyzed biaryl coupling of heteroarenes and aryl halides/triflates.

  Organic letters 20090416

• A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

  Current rheumatology reports 20090401

• New gout treatment approved.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090401

• Febuxostat: a new agent for lowering serum urate.

  Drugs of today (Barcelona, Spain : 1998) 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.

  Prescrire international 20090401

• Febuxostat treatment for gout: what the clinician needs to know.

  Therapeutic advances in musculoskeletal disease 20090401

• Febuxostat.

  Nature reviews. Drug discovery 20090301

• Update on emerging urate-lowering therapies.

  Current opinion in rheumatology 20090301

• Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.

  Rheumatology (Oxford, England) 20090201

• Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress.

  Vascular health and risk management 20090101

• New drugs: Febuxostat, lacosamide, and rufinamide.

  Journal of the American Pharmacists Association : JAPhA 20090101

• Gout. Novel therapies for treatment of gout and hyperuricemia.

  Arthritis research & therapy 20090101

• Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?

  Arthritis research & therapy 20090101

• The role of urate and xanthine oxidase in vascular oxidative stress: future directions.

  Therapeutics and clinical risk management 20090101

• Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.

  Core evidence 20090101

• Febuxostat in the management of hyperuricemia and chronic gout: a review.

  Therapeutics and clinical risk management 20081201

• Gout management: let's get it right this time.

  Arthritis and rheumatism 20081115

• Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

  Arthritis and rheumatism 20081115

• Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice.

  Journal of cardiac failure 20081101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20081001

• The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.

  Journal of clinical pharmacology 20080901

• Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.

  Nucleosides, nucleotides & nucleic acids 20080601

• In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.

  Xenobiotica; the fate of foreign compounds in biological systems 20080501

• Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080401

• Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.

  American journal of physiology. Renal physiology 20080401

• [Inhibitors of xanthine oxidoreductase].

  Nihon rinsho. Japanese journal of clinical medicine 20080401

• [New antihyperuricemic medicine: febuxostat, Puricase, etc].

  Nihon rinsho. Japanese journal of clinical medicine 20080401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080401

• Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

  British journal of clinical pharmacology 20080301

• Refractory gout: what is it and what to do about it?

  Current opinion in rheumatology 20080301

• Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.

  Life sciences 20080227

• Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20080201

• Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.

  Nephron. Physiology 20080101

• A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

  Drug safety 20080101

• Febuxostat.

  Drugs 20080101

• Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.

  Drugs 20080101

• Febuxostat : a viewpoint by Naomi Schlesinger.

  Drugs 20080101

• Febuxostat : a viewpoint by N. Lawrence Edwards.

  Drugs 20080101

• Developments in the scientific and clinical understanding of gout.

  Arthritis research & therapy 20080101

• Assessment of outcome in clinical trials of gout--a review of current measures.

  Rheumatology (Oxford, England) 20071201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071201

• [Crystal-induced arthritis--old but important].

  Zeitschrift fur Rheumatologie 20070701

• Tumor lysis syndrome.

  Seminars in thrombosis and hemostasis 20070601

• Uricase and other novel agents for the management of patients with treatment-failure gout.

  Current rheumatology reports 20070601

• Emerging therapies in the long-term management of hyperuricaemia and gout.

  Internal medicine journal 20070401

• Therapeutic advances in gout.

  Current opinion in rheumatology 20070301

• Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.

  Recent patents on inflammation & allergy drug discovery 20070201

• Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.

  International journal of medical sciences 20070101

• Hyperuricemia and gout: new insights into pathogenesis and treatment.

  Bulletin of the NYU hospital for joint diseases 20070101

• Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.

  The Annals of pharmacotherapy 20061201

• Case 8: initiation of urate-lowering therapy for standard advanced gout.

  The American journal of medicine 20061101

• Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure.

  Journal of cardiovascular pharmacology 20061101

• Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness.

  International journal of clinical practice 20061001

• [Febuxostat versus allopurinol for hyperuricemia].

  Medizinische Monatsschrift fur Pharmazeuten 20061001

• Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs.

  Journal of clinical pharmacology 20060801

• Febuxostat for prevention of gout attacks.

  Issues in emerging health technologies 20060801

• Gout's not just for the gluttonous.

  The Johns Hopkins medical letter health after 50 20060601

• New developments in clinically relevant mechanisms and treatment of hyperuricemia.

  Current rheumatology reports 20060601

• Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?

  Nature clinical practice. Rheumatology 20060501

• Febuxostat versus allopurinol for gout.

  The New England journal of medicine 20060406

• Febuxostat versus allopurinol for gout.

  The New England journal of medicine 20060406

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060401

• Newer therapeutic approaches: gout.

  Rheumatic diseases clinics of North America 20060201

• [Gout].

  Revue medicale suisse 20060111

• The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.

  Journal of clinical pharmacology 20060101

• A concise history of gout and hyperuricemia and their treatment.

  Arthritis research & therapy 20060101

• Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.

  Arthritis research & therapy 20060101

• Advances in the management of gout and hyperuricaemia.

  Scandinavian journal of rheumatology 20060101

• Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.

  Clinical pharmacokinetics 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Pathophysiology, clinical presentation and treatment of gout.

  Drugs 20060101

• Metabolic diseases: gout.

  Clinics in dermatology 20060101

• Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

  The New England journal of medicine 20051208

• Febuxostat--treatment for hyperuricemia and gout?

  The New England journal of medicine 20051208

• An update on the treatment options for gout and calcium pyrophosphate deposition.

  Expert opinion on pharmacotherapy 20051101

• Febuxostat (Teijin/Ipsen/TAP).

  Current opinion in investigational drugs (London, England : 2000) 20051101

• Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.

  Expert opinion on investigational drugs 20050701

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Recent advances in the management of gout and hyperuricemia.

  Current opinion in rheumatology 20050501

• Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

  Life sciences 20050304

• Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

  Arthritis and rheumatism 20050301

• Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.

  American journal of therapeutics 20050101

• Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.

  The Journal of pharmacology and experimental therapeutics 20041101

• Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.

  Nucleosides, nucleotides & nucleic acids 20041001

• PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.

  Nucleosides, nucleotides & nucleic acids 20041001

• Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.

  Nucleosides, nucleotides & nucleic acids 20041001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040901

• Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

  Current rheumatology reports 20040601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031201

• An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.

  The Journal of biological chemistry 20030117

• [Development antihyperuricemic candidates].

  Nihon rinsho. Japanese journal of clinical medicine 20030101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20030101